Lv1
60 积分 2024-03-06 加入
Validation of risk stratification and novel prognostic biomarkers in asian adult HSCT recipients with TA-TMA: A multicenter real-world study
1个月前
已完结
How I treat patients with AML using azacitidine and venetoclax
1个月前
已完结
The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification
3个月前
已完结
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial
4个月前
已完结
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—An open‐label, phase I/II study
4个月前
已完结
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—An open-label, phase I/II study
4个月前
已完结
Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia
4个月前
已完结
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
4个月前
已完结
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
6个月前
已关闭
皖公网安备34019202002308
